Evercore ISI raises price target for Kiniksa Pharmaceuticals (NASDAQ:KNSA) to $30.00, maintaining an "outperform" rating.
Evercore ISI raises price target for Kiniksa Pharmaceuticals (NASDAQ:KNSA) to $30.00, maintaining an "outperform" rating. The company, with a market cap of $1.26 billion, focuses on treating diseases with significant unmet medical needs. Wedbush also reaffirms "Outperform" rating with a $30.00 price target, while Kiniksa reported Q1 2024 EPS of ($0.25), missing analyst estimates by ($0.11).
April 27, 2024
3 Articles